Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04444050 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

A Phase 1 study of Healthy Participants, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target
2
Study locations

NCT04444050 is a Phase 1 study of Healthy Participants that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 48 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (26% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04444050, a Phase 1 study of Healthy Participants, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, drug levels and drug effects of single and multiple oral doses of BMS-986331 versus placebo in healthy participants and healthy Japanese participants.

Conditions Studied

Interventions

  • DRUG BMS-986331
  • OTHER Placebo, Matching BMS-986331

Study Locations (2)

California

  • Local Institution - 0001 - Anaheim

Kansas

  • ICON (LPRA) - Lenexa - Lenexa

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2020-06-23
Est. Completion 2021-05-19
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT04444050

The ClinicalTrials.gov registry entry for NCT04444050 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (26% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which BMS-986331 is the first listed.

NCT04444050 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Kansas.

Frequently Asked Questions

What is clinical trial NCT04444050 about?

NCT04444050 is a clinical study titled "Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants". The purpose of this study is to evaluate the safety, tolerability, drug levels and drug effects of single and multiple oral doses of BMS-986331 versus placebo in healthy participants and healthy Japanese participants.

What is the current status of trial NCT04444050?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2020-06-23. Estimated completion is 2021-05-19.

What conditions does trial NCT04444050 study?

This clinical trial studies the following conditions: Healthy Participants.

What interventions are being tested in trial NCT04444050?

The interventions under investigation include: BMS-986331 (DRUG), Placebo, Matching BMS-986331 (OTHER).

Who is sponsoring clinical trial NCT04444050?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04444050 being conducted?

This trial has 2 study locations across California, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.